Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
Don Deyo, Executive Chair at Reach Neuro, Inc., shared on LinkedIn about a recent article by Roberto M. de Freitas et al, published in Nature Medicine, adding:
”I am excited to share that the clinical research underlying Reach Neuro‘s breakthrough therapy for post-stroke upper limb impairment has been published in Nature Medicine.
For stroke survivors, the loss of arm and hand function can have a profound impact on independence and quality of life.
This study demonstrates that targeted spinal cord stimulation can significantly improve arm strength, mobility, and dexterity, even years after a stroke.
This publication represents an important milestone in the journey to bring a transformative therapy to the millions of people living with chronic stroke-related disability.
It is a testament to the vision, dedication, and scientific excellence of the researchers, clinicians, engineers, and study participants who made this work possible.
As Executive Chairman of Reach Neuro, I am honored to work alongside such an exceptional team as we advance this technology toward broader clinical application.
My congratulations and gratitude go to Dr. Marco Capogrosso, Dr. Peter Gerszten, Dr. Douglas Weber, Dr. Elvira Pirondini, their collaborators, and the study participants whose commitment made this achievement possible.
Read more about the publication and its significance.”
Title: Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial
Authors: Roberto M. de Freitas, Shovan Bhatia, Erynn Sorensen, Nikhil Verma, Erick Carranza, Scott Ensel, Luigi Borda, Amy Boos, Jeff Goldsmith, Lee E. Fisher, Daryl P. Fields, Marc P. Powell, Shane Gordon, Jeffrey Balzer, Robert M. Friedlander, George F. Wittenberg, Peter C. Gerszten, John W. Krakauer, Elvira Pirondini, Douglas J. Weber, Marco Capogrosso
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease